Firms test new use for enzyme technology

2 July 2020
2019_biotech_genetic_test_biomarker_targeted_big

A licensing deal with Sarepta Therapeutics (Nasdaq: SRPT) could be worth over $400 million to Lund-based enzyme specialist Hansa Biopharma (STO: HNSA).

The Swedish firm, which is working on immunomodulatory enzyme technology for rare IgG mediated diseases, will receive $10 million upfront and up to $397 million in milestones should all go well.

Sarepta will receive an exclusive, global license to develop and promote Idefirix (imlifidase) as a pre-treatment to enable Sarepta gene therapy in Duchenne muscular dystrophy (DMD) and Limb-girdle muscular dystrophy (LGMD).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology